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Caseous lymphadenitis (CLA) is a chronic disease that affects sheep and goats worldwide, and its etiological agent
is Corynebacterium pseudotuberculosis. Despite the economic losses caused by CLA, there is little information about
the molecular mechanisms of bacterial pathogenesis, and current immune prophylaxis against infection has been
unable to reduce the incidence of CLA in goats. Recently, 21 different mutant strains of C. pseudotuberculosis were
identified by random mutagenesis. In this study, these previously generated mutants were used in mice vaccination
trials to develop new immunogens against CLA. Based on this analysis, CZ171053, an iron-acquisition-deficient
mutant strain, was selected. After challenge with a virulent strain, 80% of the animals that were immunized with
the CZ171053 strain survived. Furthermore, this vaccination elicited both humoral and cellular responses. Intracellular
survival of the bacterium was determined using murine J774 cells; in this assay, the CZ171053 had reduced intracellular
viability. Because iron acquisition in intracellular bacteria is considered one of their most important virulence factors
during infection, these results demonstrate the immunogenic potential of this mutant against CLA.Introduction
Corynebacterium pseudotuberculosis is a facultative gram-
positive intracellular pathogen that is the etiological agent
of caseous lymphadenitis (CLA) in sheep and goats. CLA
is a chronic debilitating infection, and its main symptoms
can be divided into external CLA, which affects superficial
lymph nodes, and internal CLA, which leads to the devel-
opment of abscesses in internal lymph nodes and organs,
including the liver, lungs and kidneys [1-3]. This disease
has a worldwide distribution and causes economic losses
in several countries, principally to producers in developing
countries such as Brazil, where sheep and goat breeding
are of increasing economic importance [4-10].
Once established in a herd, CLA is difficult to treat be-
cause it is generally refractory to antibiotic therapy, which
is also very expensive [11]. Therefore, several studies have* Correspondence: vascoariston@gmail.com
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control CLA. Although these vaccines are useful and offer
reasonable protection, there are several problems associ-
ated with their use. All of these vaccines need to be ad-
ministered at least twice, which contributes to the misuse
of the vaccines by farmers and increases the cost. Further-
more, not all vaccines available for use in goats have the
same efficacy in sheep, and they are not licensed in all
countries [2,12]. Some experimental vaccines have been
tested using different strategies such as vaccines using
attenuated or inactivated bacteria, cell wall fractions
and DNA [13-25]. These vaccines confer variable levels
of protection, but their safety profiles remain question-
able mainly because their side effects, which are more
intense in goats. These side effects include the forma-
tion of lesions or abscesses at the injection site, fever,
malaise and reduced milk production [26,27].
Driven by the paucity of information on the molecular
basis of C. pseudotuberculosis virulence, we identified and
characterized bacterial genes based on the cellular locali-
zation of their products, focusing mainly on those proteinsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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we used, for the first time in this species, a reporter
transposon-based system named TnFuZ [28]. Using this
tool, we identified 34 mutants exhibiting a blue phenotype
from a repertoire of 1500 kanamycin-resistant mutants
[3]. By sequencing the transposon insertion site in these
mutants, we identified 21 different loci encoding fimbrial
and transport subunits, hypothetical proteins and proteins
with unknown-function in C. pseudotuberculosis. In this
present study, we tested these mutants in immunization
assays to assess their virulence potential and their capacity
to protect mice against challenge. Furthermore, we stud-
ied the cytokine and immunoglobulin production induced
by the best vaccine candidates.
Materials and methods
Bacterial strains and growth conditions
The following strains were used: the previously generated
C. pseudotuberculosis TnFuZ recombinant strains [3], the
T1 pathogenic wild-type parental strain and the caprine-
pathogenic MIC-6 strain. The strains were grown aerob-
ically in Brain Heart Infusion broth (BHI, Oxoid Ltd.,
Hampshire, England) at 37 °C. The mutant strains were
grown in the presence of kanamycin (kanamycin sulphate,
25 μg/mL; solid and liquid media) and 5-bromo-4-chloro-
3-indolylphosphate (BCIP, 40 μg/mL; Sigma-Aldrich Co.,
St. Louis, MO, USA; solid medium), a substrate that al-
lows the recovery of C. pseudotuberculosis insertional mu-
tant colonies with positive alkaline phosphatase activity.
Animal model
One hundred fifty BALB/c mice between six and eight
weeks of age, that were susceptible to C. pseudotuberculosis
infection, were used in this assay. They were provided by
the Animal Care Facility of the Biological Sciences Institute
from the Federal University of Minas Gerais and were
handled according to the guidelines of the UFMG Ethics
Committee on Animal Testing.
Immunization assay, challenge and assessment of
protection level
The immunization schedule was as follows: twenty-two
groups of five mice each were intraperitoneally inocu-
lated with 2 × 106 Colony forming unit (CFU) of each
mutant strain (CZ171049 and CZ171061 with different
transposon insertions), with was, the same dose used by
Simmons et al. [23]. Another group of five animals re-
ceived the T1 wild-type strain under the same conditions,
and a 24th group of five mice was inoculated with 100 μL
of saline solution (0.9% NaCl). The mice were intraperito-
neally challenged 21 days after immunization with 2 × 106
C.F.U of the C. pseudotuberculosis MIC-6 virulent strain.
The protection conferred by the immunization process
was evaluated by comparing the survival of the immunizedanimals to those inoculated with the T1 wild-type strain
and saline solution. The mice were evaluated for four
weeks after challenge.
For the second immunization assay, three groups of
ten mice each were inoculated with 2 × 106 CFU of the
CZ171053 strain, 2 × 106 CFU of the T1 strain or 100 μL
of saline solution. The immune protection was evaluated
using the procedure described above.
Detection of specific IgG, IgG1 and IgG2a antibodies
Serum samples were taken 21 days after immuniza-
tion. Blood samples were collected through retro-orbital
bleeding. After coagulation, the blood was centrifuged at
3000 rpm for ten minutes. The serum samples were col-
lected and stored at −20 °C. These samples were ana-
lysed using an enzyme-linked immunosorbent assay
(ELISA) to measure the total levels of specific IgG, IgG1
and IgG2a antibodies. The plates were incubated with
200 μL of the supernatant of a MIC-6C. pseudotuberculosis
culture grown for 72 h (total protein concentration of
4 μg/mL); the plates were then incubated for 18 h at 4 °C.
The wells were blocked with 0.1% Tween 20 and 10% fat-
free milk powder in PBS (pH 7.4) for two hours at room
temperature. The plates were then incubated with 100 μL
of the serum samples, diluted 1:50 in PBS-Tween, for one
hour at 37 °C. The wells were washed three times with
PBS-Tween between incubations. Anti-mouse IgG conju-
gated to horseradish peroxidase (Promega, Madison, WI,
USA) was diluted 1:10 000 in PBS-Tween and added to
the wells, and the plates were incubated for one hour at
37 °C. The same procedure was performed with horse-
radish peroxidase-conjugated anti-mouse IgG1 (Promega)
diluted 1:5000 and anti-mouse IgG2a (Promega) (diluted
1: 2000). The plates were developed with 200 pmol of
o-phenylenediamine (Sigma) and 0.05% H2O2, for ten
minutes, and the reaction was stopped with 50 μL of
2 N H2SO4. After incubation for ten minutes at room
temperature, the optical density at 492 nm (OD492)
was measured.
Cytokine analysis
For the cytokine analysis, five immunized mice from the
CZ171053-, T1- and saline-infected groups were sacrificed
before challenge, and their spleens were collected aseptic-
ally. Erythrocytes were removed by treatment with 0.017 M
Tris-ammonium chloride, and the remaining leukocytes
were washed twice with PBS (pH 7.4) and suspended in
RPMI (RPMI-1640; Gibco BRL, Life technologies, Carlsbad,
CA, USA) containing 10% fetal bovine serum, 100 U/mL
penicillin and 100 μg/mL streptomycin. After adjusting the
cellular concentrations to 5 × 106 viable cells/mL in 100 μL,
the samples were seeded in 96-well tissue culture plates.
The cells were stimulated with the supernatant of a 72-h
MIC-6C. pseudotuberculosis culture (protein concentration
Figure 1 Percentage of immunized animals protected from the
experimental challenge with C. pseudotuberculosis. Twenty-one
days after immunization with recombinant strains of C. pseudotuberculosis,
the animals were challenged with 106 C.F.U. of the MIC-6 virulent
wild-type strain. Protection was defined as the survival of the immunized
mice for four weeks after the challenge. Bars marked with (a) and
(b) correspond to the mutants tested three times and five times,
respectively. *p < 0.05, **p < 0.01, ***p < 0.001 versus control
(ANOVA, post-test Bonferroni).
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lated with concanavalin A (2 μg/mL; Sigma), and culture
medium was added to the negative control wells. The su-
pernatants were collected 24 h after stimulation and used
for IL-4, IL-10, IFN-γ and TNF-α quantification using com-
mercial sandwich ELISA kits (Duo Set ELISA Development
System, R&D Systems, Minneapolis, MN, USA), according
to the manufacturer’s instructions.
Determination of intracellular survival
J774 macrophage-like cells, derived from murine lymph-
oma were cultivated in Dulbecco’s modified Eagle essen-
tial medium (DMEM, Sigma) supplemented with 5% fetal
bovine serum, 50 μg/mL gentamicin and 2.5 μg/mL fungi-
zone at 37 °C in a 5% CO2 atmosphere. The CZ171053
mutant strain and T1 wild-type strain were grown for
48 h at 37 °C, washed three times with PBS, resuspended
in DMEM to at a concentration of 106 CFU/mL and used
to infect J774 cells (10 bacteria: 1 cell). For the determin-
ation of intracellular viability, the infected J774 mono-
layers were washed six times with PBS and treated with
150 μg/mL gentamicin sulphate (Sigma) then diluted in
DMEM for one hour after one, three and six hours of in-
cubation. The cells were washed six times with PBS to
eliminate the dead bacteria in the extracellular medium.
The monolayers were lysed with 0.5 mL of 0.1% TritonX-
100 (Sigma) in PBS, and the supernatant was plated on
BHI agar. The number of intracellular bacteria was deter-
mined by counting the number of CFU.
Statistical analysis
The results were expressed as the mean ± standard devi-
ation. The differences among the experimental groups
were calculated using one-way ANOVA followed by the
Bonferroni (post-test levels of protection and immuno-
globulin and cytokine production) or Tukey’s (intracellu-
lar viability) tests. The data were considered significantly
different when p < 0.05. Both tests were performed using
GraphPad Prism version 5.00 for Windows (GraphPad
Software, San Diego, CA, USA) [30].
Results
Immunization assay, challenge and assessment of
protection level
Using a transposon-based random mutagenesis system,
34 alkaline phosphatase-positive recombinant strains of
C. pseudotuberculosis were obtained; in these strains
transposon insertions were identified at 21 different loci.
In this study, 22 of the mutant strains were tested in
mice vaccination trials to select potential immunogenic
candidates against caseous lymphadenitis.
Mice that were inoculated with the CZ171053 recom-
binant C. pseudotuberculosis strain, which is an iron-
acquisition-defective mutant, showed the best protectionlevel; 80% of the mice immunized with this strain sur-
vived after challenge with the virulent strain (Figure 1).
The mice immunized with other mutants did not ac-
quire a protection level above 60% (CZ171049). The ani-
mals immunized with the T1 wild-type strain did not
survive long enough to be challenged; all of these mice
died three days after immunization.
After selection of the CZ171053 strain as a potential
immunogenic candidate, a new immunization assay was
performed to evaluate the immunoglobulin- and cytokine-
induction profiles after immunization. Three groups of ten
mice received the CZ171053 mutant, T1 wild-type strain
or 100 μL of saline solution according the immunization
schedule described above. Serum samples and splenocytes
were collected 21 days after immunization.
In this second experiment, inoculation with the CZ17
1053 strain protected 80% of the MIC-6-challenged mice
(Figure 2). The animals that were inoculated with the T1
wild-type strain did not survive until they were challenged
with the MIC-6 strain, and all animals from the control
group died within eighteen days of inoculation with the
MIC-6 strain.
Detection of specific IgG, IgG1 and IgG2a antibodies
The serum samples from mice immunized with the
CZ171053 strain were tested by ELISA 21 days after
immunization to detect the production of specific IgG,
IgG1 and IgG2a antibodies. IgG1 and IgG2a were investi-
gated separately because IgG1 is related to a Th2 cellular
immune response, whereas IgG2a is related to a Th1 re-
sponse in the same species. The ELISA analysis revealed
that mice immunized with the CZ171053 strain produced
Figure 2 Kinetics of the survival of animals immunized with the
CZ171053 recombinant strain of C. pseudotuberculosis. The lines
show the daily percentage of survival of the immunized mice
challenged with 106 CFU of the MIC-6 virulent wild-type strain for
four weeks post-infection. The data are from a representative experiment
using ten mice per group.
Figure 4 Cytokine detection in the supernatant of cultured
mouse splenocytes that were isolated and pooled from
CZ171053-vaccinated mice. The bars represent the mean ± standard
deviation of a representative experiment using five mice per group.
***p < 0.001 versus control (ANOVA, post-test Bonferroni).
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IgG, IgG1 and IgG2a than the control mice (Figure 3), in-
dicating that the humoral immune response was activated
by the immunization.Cytokine analysis
The cellular immune responses after immunization with
the CZ171053 strain were evaluated by measuring cyto-
kine production using the culture supernatants of stimu-
lated splenocytes. As shown in Figure 4, although no
significant production of IFN-γ or TNF-α was detected,
IL-4 and IL-10 were efficiently produced.Figure 3 Serological response of the mice following immunization
with the CZ171053 recombinant strain of C. pseudotuberculosis.
The mice were bled 21 days after immunization, and the production
of specific IgGs and their subtypes, IgG1 and IgG2a, was measured
by ELISA analysis. The bars represent the mean ± standard deviation
obtained in a representative experiment using ten mice per
group. *p < 0.05, **p < 0.01, ***p < 0.001 versus control (ANOVA,
post-test Bonferroni).Intracellular survival determination
The recombinant strain CZ171053 was submitted to
intracellular viability analysis after one, three and six hours
of interaction with a monolayer of J774 macrophage-like
cells (Figure 5). We observed that after one hour of infec-
tion, the CZ171053 strain penetrated the cells more effi-
ciently than the T1 wild-type strain. However, after three
hours, the CZ171053 strain was essentially unable to sur-
vive inside the cells, suggesting that the mutation might
impede its ability to persist inside the host. The analysis of
the host-pathogen interaction after six hours revealed thatFigure 5 Intracellular viability of the CZ171053 strain of C.
pseudotuberculosis after one, three and six hours of interaction
with J774 cells. The values at each time-point represent the number
of viable bacteria recovered relative to the number recovered at the
previous time-point, expressed as a percentage. The results are
expressed as the mean ± standard deviation of two representative
experiments performed in quadruplicate. *** represents a significant
reduction in viability relative to the T1 wild-type (wt) strain at p< 0.0001
(ANOVA, Tukey’s test).
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lower than with that of the T1 wild-type strain.Discussion
The results presented here are surprising because IFN-γ
and TNF-α, which are important for the host defence
against C. pseudotuberculosis infection [23,31], were not
detected in significant levels in the immunized mice. We
cannot exclude the possibility that this unexpected find-
ing is due to the late time-point at which the cytokine
levels were analysed. Simmons et al. [23] evaluated IFN-
γ production on the seventh and fourteenth days after
the vaccination of mice with live C. pseudotuberculosis
and qualitatively detected the production of this cytokine
on day 7, but not on day 14, suggesting a self-limiting
profile of the immune response. The high production of
IL-10 at a late time-point after inoculation was described
by Paule et al. [32] and could be responsible for the low
IFN-γ production; this observation suggests that an im-
mune modulatory profile might underlie the inhibition
of IFN- γ production observed in our experiments [33].
Additionally, this regulatory profile could be a conse-
quence of an inflammatory reaction that led to the switch
from aTh1 to a Th2 profile because cytokines typical of this
profile were detected in our ELISA analyses. Furthermore,
Paule et al. [32] observed that after caprine-immunization
some animals did not produce IFN-γ but still presented sig-
nificant protection against the infectious challenge. More
accurate analyses should be performed to elucidate the im-
munological protection mechanisms that are induced by
the CZ171053 strain in mice. In our experiments, cytokine
production was evaluated 21 days after immunization, and
the profile observed might be a modulatory profile after the
initial immune response.
Our data on the immune protection, production of
immunoglobulins and cytokines and intracellular viabil-
ity suggest that the CZ171053 mutant has a reduced
ability to survive inside the host cells but is still able to
induce immunoglobulin and cytokine production. Fur-
thermore, these results are suggestive of attenuation used
by an iron-acquisition deficiency. Iron acquisition is essen-
tial for bacterial growth in vivo and the protein encoded
by the gene that was disrupted in this mutant, ciuA (Gene
ID: 9448933), is involved in the transport of iron from fer-
ric citrate. The inability of this mutant to acquire iron
might be important for attenuation. The mutant bacteria
that invade the host cells are recognized by the immune
system and, most importantly, protect the immunized
mice upon challenge with a virulent strain. These results,
which were obtained using a murine model, suggest that
the CZ171053 strain may be used as a potential live vac-
cine against CLA in other animals such as goats and
sheep, which are natural hosts for C. pseudotuberculosis.Competing interests
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